2026 Guidance Raised -- Revenue expected at $4.3-$4.4 billion, EBITDA forecasted at $345-$360 million, driven by Q1 performance and inclusion of SCNM. Contract Mix Balance -- Maintained at roughly 50% ...

The Board of Directors that met on 7 May 2026 approved this unaudited trading update for the nine-month period ended 31 March ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q1 2026 Earnings Call Transcript May 12, 2026 Acurx Pharmaceuticals, Inc. misses ...

Life-sciences stocks in oncology diagnostics, precision medicine and research tools seen offering strong growth potential.

From 2019 through now, Amneal revenues have grown 11% and adjusted EBITDA has grown 13% on a CAGR basis. With growth in each ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo California, Colorado, Minnesota, New York, Connecticut, Oregon and Washington have all passed ...

XRP’s 10% rally to $1.44 is the first time in a while the price is testing the $1.45 resistance with multiple catalysts and real momentum behind—Rakuten’s payment integration, Ripple’s Kyobo Life ...

Iran’s push to formalise the tolling of vessels transiting the Strait of Hormuz alongside what appears like a positive ...

Rather than endanger their US profits, drugmakers withhold new medicines ...

RENTON — Would the Seahawks stick and use their pick with the last selection of the first round of Thursday’s NFL draft? Or would they wheel and deal and wait until Friday to add to the roster that ...